Further studies will focus on the effectiveness of AAV-Syn-BDNF-eGFP and AAV-Syn-GDNF-eGFP as therapeutic agents in provoking seizure activity in mutant mice with a genetic predisposition to epilepsy. This evidence concerns the gene GDNF and epilepsy.